ConductScience.org, home

Paper9649162

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

Warner E and 10 others. Br J Cancer, 1998. Cited by 33 papers, by iCite.

Cite this record

ConductScience Library. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Papers, record 9649162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9649162

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
PubMed
Journal
Br J Cancer
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
0.81
iCite
Revised in PubMed
2019-05-15
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Warner EE
2Goel RR
3Chang JJ
4Chow WW
5Verma SS
6Dancey JJ
7Franssen EE
8Dulude HH
9Girouard MM
10Correia JJ
11Gallant GG

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Neoplasms, Unknown PrimaryMajor topic
Administration, Oral
Adult
Aged
Carboplatin
Dose-Response Relationship, Drug
Drug Administration Schedule
Etoposide
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14748282Letter: Creatinine clearance: bedside estimate.Ann Intern Med1973https://conductscience.org/library/papers/4748282PubMed
29196154Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.J Clin Oncol1997https://conductscience.org/library/papers/9196154PubMed
33933808Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin.CMAJ1985https://conductscience.org/library/papers/3933808PubMed
43548315Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.Am J Clin Oncol1987https://conductscience.org/library/papers/3548315PubMed
52918334Chronic daily administration of oral etoposide--a phase I trial.J Clin Oncol1989https://conductscience.org/library/papers/2918334PubMed
62669133The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.Semin Oncol1989https://conductscience.org/library/papers/2669133PubMed
72681557Carboplatin dosage: prospective evaluation of a simple formula based on renal function.J Clin Oncol1989https://conductscience.org/library/papers/2681557PubMed
82154857Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.Semin Oncol1990https://conductscience.org/library/papers/2154857PubMed
92154858Phase II study of daily oral etoposide in refractory germ cell tumors.Semin Oncol1990https://conductscience.org/library/papers/2154858PubMed
101984833The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.Cancer1991https://conductscience.org/library/papers/1984833PubMed
111888154High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.Anticancer Res1991https://conductscience.org/library/papers/1888154PubMed
127684858Empirical chemotherapy for adenocarcinoma of unknown primary tumor site.Semin Oncol1993https://conductscience.org/library/papers/7684858PubMed
138316270Treatment of patients with cancer of an unknown primary site.N Engl J Med1993https://conductscience.org/library/papers/8316270PubMed
148156538Unknown primary tumours.Cancer Treat Rev1994https://conductscience.org/library/papers/8156538PubMed
157636553Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.J Clin Oncol1995https://conductscience.org/library/papers/7636553PubMed
166321006VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer.Cancer1984https://conductscience.org/library/papers/6321006PubMed

Download CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
41749818Ten-Year Experience in the Treatment of Cancers of Unknown Primary from Poland: From Overall Survival to Factors Influencing Response in the Prepersonalization Era.Cancers (Basel)2026https://conductscience.org/library/papers/41749818PubMed
41122443Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population.J Res Med Sci2025https://conductscience.org/library/papers/41122443PubMed
40242159Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine.MedComm (2020)2025https://conductscience.org/library/papers/40242159PubMed
39033323Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.Mol Ther2024https://conductscience.org/library/papers/39033323PubMed
34075699MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.Mol Oncol2021https://conductscience.org/library/papers/34075699PubMed
33504059Cancer of Unknown Primary: Challenges and Progress in Clinical Management.Cancers (Basel)2021https://conductscience.org/library/papers/33504059PubMed
32010631"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?Front Oncol2019https://conductscience.org/library/papers/32010631PubMed
28515916ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site.Mol Clin Oncol2017https://conductscience.org/library/papers/28515916PubMed
19424663Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis.Invest New Drugs2010https://conductscience.org/library/papers/19424663PubMed
17180509Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.Int J Clin Oncol2006https://conductscience.org/library/papers/17180509PubMed
15138469Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.Br J Cancer2004https://conductscience.org/library/papers/15138469PubMed
11953879A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.Br J Cancer2002https://conductscience.org/library/papers/11953879PubMed
11429061Treatable subsets in cancer of unknown primary origin.Jpn J Cancer Res2001https://conductscience.org/library/papers/11429061PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9649162

GET https://conductscience.org/api/papers/v1/9649162/authors